Analyte meter with a moveable head and methods of using the same

Abstract
The present disclosure provides in vitro analyte meters that include a meter portion that is moveable relative to at least one other meter portion. Embodiments include moveable meters that are integrated with in vivo analyte systems. Also provided are methods, systems and kits.
Description
BACKGROUND

Analytical analyte testers and meters are often used in chemistry and medicine to determine the presence and/or concentration of a biological analyte of interest. For example, such analytical testers and meters are used to monitor glucose in diabetic patients and lactate during critical care events.


Many currently available analyte meters are configured such that an in vitro analyte tester, oftentimes in the form of a test strip, is inserted into the analyte meter for the testing process. Such meters include in vitro analyte test strip ports to receive analyte sensors for testing. Conventional analyte meters have in vitro analyte test strip ports that have fixed arrangements, i.e., sensor ports in fixed or immovable positions relative to the rest of the meter. Because of this, after obtaining a sample of biological fluid for analyte testing, a user may have to change the orientation of the meter in order to view analyte test results that are displayed on a display of the meter. This fixed orientation of the sensor port relative to other portions of a meter may complicate and make difficult the testing process. For example, users of an analyte meter may have physical ailments, e.g., as a result of a health condition, that make testing using a fixed-oriented meter challenging. In the context of diabetes care, manual dexterity, vision, and the like may be compromised. These and other problems may be compounded when a user is very young or very old.


It would therefore be desirable and useful to develop analyte meters, e.g., glucose testing meters, that are easy to use and do not require a user to change the orientation of the meter in order to obtain test results.


SUMMARY

The present disclosure provides devices and methods for analyte testing. Embodiments include analyte meters having adjustable in vitro analyte test strip contacting areas that can be adjusted to a particular test site. Included herein are analyte meters having moveable in vitro analyte test strip ports relative to at least a portion of a meter. The meters and methods therefore are designed to detect and/or quantify analyte levels in a fluid sample. The meters may be characterized as in vitro meters in that they test for analyte in a sample withdrawn from a user and applied to an in vitro analyte test strip that is not implanted in the user. In other words, the meters are for ex-vivo analyte testing. As described below, the in vitro meters may be combined with in vivo analyte testing systems to provide an integrated system.


Embodiments include analyte meters, e.g., glucose meters that include programming to test glucose in a biological sample, having a housing that includes a first portion and at least a second portion coupled to the first portion by a connector portion. The first meter portion includes an in vitro analyte test strip engaging area, e.g., an in vitro analyte test strip port, to receive or otherwise make contact with (electrical and/or mechanical) an in vitro analyte testing device such as in the form of an in vitro analyte test strip. In further describing the invention, description will be primarily related to an analyte tester in the form of a test strip for exemplary purposes only, where such description is in no way intended to limit the scope of the invention. It is to be understood that an in vitro analyte tester may be in a variety of forms. The second meter portion may include other features and componentry of the meter, e.g., one or more controller modules, e.g., hardware and/or software, to accomplish testing of an analyte applied to a sample contacted to an in vitro analyte test strip. In certain embodiments, the second meter portion includes a reporting module to report results of an analyte test to a user, e.g., a visual display and/or an audio output module. In certain embodiments, the first meter portion is moveable relative to the second meter portion, or vice versa. The first meter portion may be moved so as not to cause movement of the second portion, and vice versa. Each of the first and second meter portions may move independently of one or more other portions of the meter. In certain embodiments, the first meter portion flexes, pivots, rotates, rolls, or otherwise moves relative to the second meter portion.


Embodiments include first meter portions that are pivotable about a pivot point relative to the second meter portion that includes a reporting module. First meter portions are moveable upwardly and/or downwardly relative to the second meter portion, and which may be lockable against upward or downward movement. For example, a first meter portion may be pivotable towards and/or away from the second meter portion, and thereafter, in one aspect, locked in the pivoted position.


In certain embodiments, a first meter portion can be caused to pitch and/or yaw and/or roll, where pitch, yaw and roll will be defined broadly herein with respect to rotations about axes x, y and z, including but not limited to rotation about the z-axis (pitch), rotation about the y-axis (yaw) and rotation about the x-axis (roll). In certain embodiments, the first portion may be caused to pitch and/or roll and/or yaw, while the second portion remains in a fixed position.


The devices may include locking mechanisms to lock a first meter portion in place in a selected position relative to at least a second meter portion. In certain aspects, selecting a desired position may include selecting a desired position from a plurality of possible selectable positions.


Embodiments include blood glucose meters dimensioned and designed for home use, e.g., and are compact, hand-holdable, and easily transportable devices. In certain embodiments, the blood glucose meters may be part of, e.g., integrated with, an in vivo analyte testing system.


These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

Referring now to the drawings, wherein like reference numerals and letters indicate corresponding structure throughout the several views:



FIG. 1 shows a frontal view of an embodiment of an adjustable in vitro analyte meter according to the present disclosure having an in vitro analyte test strip contacting portion that is moveable relative to at least one other portion of the meter such as a reporting module portion;



FIG. 2 shows a side view of the analyte meter of FIG. 1;



FIG. 3 shows a side view of the analyte meter of FIG. 1 with the in vitro analyte test strip head moveable about the meter connector through a range of motion (from about 0 to about 180 degrees);



FIG. 4 shows a perspective view of the analyte meter of FIG. 1;



FIG. 5 shows a frontal view of an embodiment of an in vivo analyte testing system that includes an in vivo analyte sensor, an in vivo sensor control unit, optional mounting unit for the in vivo sensor control unit and a receiver module, and an adjustable in vitro analyte meter according to the present disclosure that is integrated into a housing of the in vivo analyte testing system and the meter has a portion that is moveable relative to at least one other portion of the integrated housing such as a reporting module portion;



FIG. 6 shows a side view of the integrated analyte meter of FIG. 5;



FIG. 7 shows a side view of the integrated analyte meter of FIG. 5 with the in vitro analyte test strip head moveable about the meter connector through a range of motion (from about 0 to about 180 degrees); and



FIG. 8 shows a perspective view of the analyte meter of FIG. 5.





As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.


DETAILED DESCRIPTION

Before the embodiments of the present disclosure are further described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.


Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.


As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.


The present disclosure provides in vitro analyte meters designed to contact, e.g., receive, in vitro analyte test strips. The in vitro analyte meters (also referred to as single point monitors, single point blood glucose modules, blood glucose monitors or meters, and the like) are configured to process a signal received from the in vitro analyte test strip and determine a presence and/or concentration of analyte in a sample of biological fluid applied to the in vitro analyte test strip, based on the received signal. Embodiments of the in vitro meters include portions that contact in vitro analyte test strips, e.g., in vitro analyte test strip ports.


The in vitro analyte meters may be small portable devices designed and dimensioned to be palm-sized and/or adapted to fit into, for example, a pocket or purse of a patient, or comfortably worn on a belt, e.g., in a holster. The analyte meters may have the functionality and/or appearance of a personal electronic device, such as a mobile phone or personal digital assistant (PDA), so that the user may not be identified as a person using a medical device. See, e.g., U.S. Pat. Nos. 7,041,468; 6,071,391; 6,120,676; 6,143,164; 6,299,757; 6,338,790; 6,377,894; 6,600,997; 6,773,671; 6,377,894; 6,600,997; 6,773,671; 6,514,460; 6,893,545; 6,924,518, and patent application Ser. No. 12/431,672, and Patent Application Publication No. US2004/0254434, the disclosures of each of which are herein incorporated by reference. In certain embodiments, the analyte meters may be a larger unit for home use and designed to sit on a shelf or nightstand. In yet other embodiments, the analyte meters may be designed for use in a hospital or doctor's office.


The in vitro meters include a portion that is moveable, e.g., rotatable, relative to at least one other portion of the meter while maintaining the at least one other portion in a fixed position, and in many embodiments the moveable portion is moveable relative to the entirety of the rest of the meter. It will be understood that the in vitro meters described herein are described primarily with respect to in vitro analyte test strip contacting portions of the meter being moveable relative to at least one other portion of the meter for exemplary purposes only, and the at least one other portion of the meter, including the entirety of the meter, may be moved relative to the in vitro analyte test strip contacting portion while maintaining the in vitro analyte test strip contacting portion in a fixed position.


The movable in vitro analyte test strip contacting portion may move in a variety of positions. For example, the meters may include a reporting module interface area, where reporting module is used broadly to include one or more units or components that convey information to a user of the device. By way of example and as described herein, a reporting module may include a visual display integrated with the meter housing. Embodiments include in vitro test strip-contacting meter portions that are pivoted through an angle of at least 180 degrees relative to meter or the reporting module portion of the meter (see, e.g., FIGS. 2-4), e.g., about the longitudinal and/or latitudinal meter axis(es) as shown by the dotted lines L1/L2 in FIG. 2. For example, a first meter portion pivoting motion may be characterized as upward and downward motion relative to the housing (e.g., relative to the reporting module portion of the housing) or relative to a connector portion that connects the in vitro analyte test strip contacting portion to another portion of the housing and enables it to move, and may also be referred to as frontward and backward motion as related to a surface of the meter that includes one or more user interface components such as a reporting module and/or user function selectors such that frontward movement refers to moving the in vitro analyte test strip contacting portion of a meter towards such a surface and backward movement refers to moving the in vitro analyte test strip contacting portion of a meter away from such a surface. In addition to or instead of upwardly and downwardly movement, an in vitro analyte test strip contacting portion may be moved sidewardly in one or both sideward directions. The in vitro analyte test strip contacting portion or head of the in vitro meter is therefore rotatable about its longitudinal axis and/or latitudinal axis. As to upward and downward movements, in certain embodiments an in vitro analyte test strip contacting portion may be limited in downward movement, but unlimited in upward movement, and vice versa. In certain embodiments, the in vitro analyte test strip contacting portion can rotate about one or more of its axes so as to pitch and/or yaw and/or roll. In certain embodiments, an in vitro meter may have limited pitch and/or roll, and unlimited yaw angle, or any combination thereof. Accordingly, the moveable in vitro analyte test strip contacting portion may have multiple degrees of freedom.


Referring now to the Figures, FIG. 1 shows an embodiment of an in vitro analyte meter 10 having a moveable head 40. Meter 10 includes a housing 20 having a first portion or in vitro analyte test strip contacting portion 40 (the head), and at least one other portion 60, coupled together by connector 50. First portion or meter head 40 includes an in vitro analyte test strip contacting area 42 to establish contact (electrical and/or mechanical) with an in vitro analyte test strip.


In vitro analyte test strip contacting area 42 of meter 10 may be on or in the housing, herein shown as an in vitro analyte test strip port coupled to housing 20, wherein in vitro analyte test strip port 42 is configured to receive an in vitro analyte test strip 80 as shown in FIG. 4 (see also FIG. 8). In vitro analyte test strip contacting area 42 may include one or more conductive contacts to contact conductive contacts of an analyte in vitro analyte test strip contacted therewith to establish electrical contact, in the instances of electrochemical in vitro analyte test strips. In certain embodiments, meter 10 includes optional turn-on contact(s) so that the meter 10 is activated (“turned on”) to perform in vitro testing by contacting the conductive contact(s) of an in vitro test strip upon application (e.g., insertion) of an in vitro analyte test strip to the in vitro analyte test strip contact area.


Referring back to FIG. 1, second meter portion 60 may include a frontal or user interface side or wall 66 that includes one or more user interface components and an opposing side 68. As can be seen, the second meter portion 60 includes optional reporting module 62 to convey information to a user and/or enable a user and/or vice versa, e.g., to report results of an analyte test to a user. Reporting module 62 may be an audible, tactile, and/or visual reporting module, e.g., may include a display to present information such as analyte concentration, may be configured to vibrate and/or otherwise convey information to the user associated with the analyte concentration based on a series of vibratory alerts, and/or may be configured to include audible notification (e.g., may include speakers, etc.) and/or may include a voice user interface. In certain embodiments, meter 10 includes an optional display unit 62 or a port (not shown) for coupling an optional display unit to the meter 10. One or more user function selectors 64 may also be included. The manually actuatable selector(s) are arranged for convenient actuation by a user.


User function selector(s) 64 may include one or more buttons (as shown for example in the figures), knobs, jog wheel, capacitive sensing slider inputs, and/or one or more combinations thereof. In one embodiment, a user may operate one or more user function selector to navigate menus and options of reporting module 62 and to select therefrom, and may also operate input(s) to perform calculations and determinations associated with one or more medication dose calculation functions, such as a bolus dose calculation function, of the meter 10, including confirming a dose calculation prior to delivery. In a further embodiment, the one or more user function selectors may be operated to enter event marker information to the meter 10 such as, for example, meal events, exercise events and the like.


In one embodiment, user function selector 64 includes a plurality of input buttons, wherein each input button is designated for a specific task. Alternatively, one or more of the input buttons may be “soft buttons” which may be programmable or programmed in the meter 10 and selectively displayed on the display unit 62. In the case where one or more of the plurality of input buttons are “soft buttons”, these buttons may be used for a variety of functions. The variety of functions may be determined based on the operational mode of the meter 10, and may be distinguishable to a user by the use of button instructions shown on display unit 62.


Reporting module in the form of a visual display 62 may be a dot-matrix display. In some embodiments, other display types, such as liquid-crystal displays (LCD), plasma displays, high definition displays (HD), light-emitting diode (LED) displays, OLED (Organic Light Emitting Device) display, seven-segment displays, color or monochrome displays, among others, may alternatively be used. A single unit may include a plurality of different displays. Display unit 62 may be configured to provide an alphanumeric display, a graphical display, a video display, an audio display, a vibratory output, or one or more combinations thereof. The display unit 62 can also be configured to provide, for example, information related to a patient's current analyte concentration as well as predictive analyte concentrations, such as trending information, and/or prior monitored analyte concentrations (for example, by a chart or a graph, numeric display over a predetermined time period).


In some embodiments, display unit 62 is a touch sensitive display in which information or commands may be entered via the display using, for example, a stylus or any other suitable input device, and where the touch sensitive display may be configured as the user interface in an icon driven environment, for example.


Referring again to FIG. 1, in certain embodiments, connector 50 couples first meter portion 40 to second meter portion 60 and enables them to selectively move independently of each other. Connector 50 may be any suitable mechanism that enables movement of first portion 40 relative to second portion 60. Connector 50 may include ball and socket, articulating joint, universal joint, rotary joint, pawl/ratchet, gliding joint, hinge joint, anchored pivot, and the like. The in vitro analyte test strip contacting portion 40 may be pivotally mounted to other meter portion 60 to allow in vitro analyte test strip contacting portion to pivot about a pivot point 52 (for example, shown in FIG. 2) through a wide range of angled motion. Connector 50 thus defines a pivot axis about which in vitro analyte test strip contacting portion 40 pivots.


Connector 50 may include a movement lock or otherwise resist movement (gravity resistant), unless a force is applied thereto (or the movement lock is unlocked) to move it. In this manner, in vitro analyte test strip contacting portion 40 may be locked in place in any of a plurality of selectable positions. For example, in certain embodiments, when connector 50 is caused to move, an engaged locking mechanism may be disengaged to allow uninhibited movement of the in vitro analyte test strip contacting portion, and re-engaged to lock the in vitro analyte test strip contacting portion in a selected position. A locking mechanism or the movement lock coupled to connector 50 may be engaged/disengaged simply by application of a small force to in vitro analyte test strip contacting portion 40 to move it in a direction (e.g., a light urging such as a push from a finger), or an active locking mechanism may include a user interface (e.g., button, latch, or the like) that may be engageable and actuated by a user to lock and unlock the in vitro analyte test strip contacting portion.



FIGS. 2 and 3 show side views of meter 10. FIG. 2 shows in vitro analyte test strip contacting portion 40 in a first position relative to second portion 60/reporting module 62 such that in vitro test strip port 42 of the meter 10 is substantially aligned with longitudinal axis L1, but pivotable about connector 50 through a range of motion relative to an axis such as a long axis L1 (if so definable by the meter 10 or meter portion 60) where the in vitro analyte test strip port 42 may pivot through an angle alpha (α), e.g., that may range from about −90 degrees to about +90 degrees relative to the longitudinal axis L1 of the meter 10 and/or meter portion 60 (that is, for example, the pivoting angle alpha (α) defining a range of approximately 180 degrees). This motion moves the in vitro analyte test strip port 42 towards or away from the user interface side 66 of the meter 10. FIG. 3 shows moveable in vitro analyte test strip head (in vitro analyte test strip contacting portion) 40 pivoted away from reporting module 62 and towards opposing side 68 such that it is rotated about connector 50 to a second position that enables easy viewing access to reporting module 62 while testing. Although it is shown in FIG. 3 a pivoting angle defining a range of approximately ±90 degrees relative to the longitudinal axis L1 of the meter 10, it is to be understood that in other embodiments, the analyte test strip contacting portion 40 may pivot a range greater than ±90 degrees relative to the longitudinal axis L1 of the meter 10 (that is, for example, the pivoting angle may be defined over a range greater than a total of 180 degrees, such as, a range of approximately 270 degrees or greater). Alternatively, the meter 10 may be configured such that the analyte test strip contacting portion 40 may have a limited pivot range, such as approximately ±45 degrees or less relative to the longitudinal axis L1 of the meter 10.



FIG. 4 shows a perspective view of the meter 10 of FIG. 3 with in vitro analyte test strip 80 being contacted with the in vitro analyte test strip contacting area 42 of meter 10 while in the bent/pivoted position relative to second portion 60 of the meter 10, making it easier for a user to contact the blood sample with the test strip and view results on display 62 at the same time, i.e., without having to re-orient the meter 10.


In a further aspect, the meter 10 may be configured with programming to automatically detect the orientation of the housing 20 such that the orientation of the displayed information is adjusted automatically (or is user settable, configurable or programmable). That is, in one embodiment, the orientation of the output display on the reporting module 62 may be programmed to adjust or automatically adjust to be reoriented based on the orientation of the housing 20 of the meter 10. For example, the numerical display representing the results of the testing (glucose value) on the reporting module 62 may be oriented in a predetermined position relative to the one or more user function selectors 64 on the housing 20 of the meter 10, depending upon the detected or positioned orientation of the second portion 60 of the meter 10 relative to the testing position of the meter 10, or relative to the pivotable in vitro analyte test strip contacting portion 40, or both. In this manner, in one aspect, the output display on the reporting module 62 may be upside down, right side up, inverted, angled (for example, at about 90 degrees relative to the plane defined by, for example, analyte test strip 80 insertion direction towards the in vitro analyte test strip port 42.


In one embodiment, meter 10 also includes a controller module (not shown) coupled to housing 20. The controller module includes hardware and software to perform and control the analyte testing functions, e.g., apply a potential to the in vitro analyte test strip, etc., and process a signal received from in vitro analyte test strip 80 to determine the presence and/or level of concentration of the analyte based on the received signal.


The controller module includes programming to process a signal received from an in vitro analyte test strip and determine a concentration of analyte, e.g., glucose, based on the signal. Details relating to the receipt of an analyte signal from an in vitro analyte test strip and the determination of a concentration of analyte are described, for example, in patents and patent applications described herein, and U.S. Pat. No. 7,041,468, the disclosure of which is incorporated by reference herein. In some embodiments, the analyte meter 10 includes a data storage unit (not shown) coupled to the controller module.


Any suitable in vitro analyte testers may be employed with the meters described herein. In vitro tests strips that may be employed include but are not limited to those described in U.S. Pat. Nos. 6,281,006; 6,103,033; 6,338,790; 6,120,676; 6,143,164, and U.S. patent application Ser. Nos. 11/225,659, now U.S. Pat. No. 8,298,389; Ser. No. 11/237,447, now U.S. Pat. No. 7,846,311; and Ser. No. 11/277,931, now U.S. Pat. No. 7,887,682, the disclosures of which are herein incorporated by reference. In vitro analyte test strips include, but are not limited to FreeStyle® test strips and Precision® analyte test strips from Abbott Diabetes Care Inc.


In certain embodiments, in vitro analyte test strips 80 and in vitro analyte meters 10 may be configured for orientation non-specific insertion of an in vitro analyte test strip into analyte meter 10. By orientation non-specific insertion, it is meant that either the first substrate or the second substrate can be upward facing when the proximal end of in vitro analyte test strip 80 is inserted into the in vitro analyte test strip port of a corresponding analyte meter. That is, either a first substrate or a second substrate of an in vitro analyte test strip can be upward facing when the proximal end of the in vitro analyte test strip is inserted into analyte meter 10. As such, orientation-non specific systems include in vitro analyte test strips that can be inserted in either of the above orientations into a meter described herein without negatively affecting the results of the assay.


A variety of analytes can be detected and quantified using the disclosed in vitro analyte test strips and meters. Analytes of particular interest include glucose and lactate. Additional analytes that may be determined include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones (e.g., ketone bodies), lactate, oxygen, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be determined. Assays suitable for determining the concentration of DNA and/or RNA are disclosed in U.S. Pat. No. 6,281,006 and U.S. Pat. No. 6,638,716, the disclosures of each of which are incorporated by reference herein.


The analyte meters described herein find use in methods for determining the concentration of an analyte in a fluid sample from a subject. Generally, these methods include inserting an in vitro analyte test strip into an analyte meter, contacting a fluid sample e.g. blood sample, interstitial fluid, sweat, tears, and the like, with the in vitro analyte in vitro analyte test strip, generating a sensor signal at the working electrode, and determining the concentration of the analyte using the generated sensor signal. Examples of certain electrochemical reactions which can be utilized to produce a sensor signal are described in detail in U.S. Pat. No. 6,592,745, the disclosure of which is incorporated by reference herein. In one embodiment, the determining step includes determining the concentration of the analyte based on amperometry, coulometry, potentiometry, and/or voltametry, including square wave voltametry, or optical techniques, using the analyte test strip. Optical analyte systems are also contemplated.


Certain embodiments may include a medication dosage determination function. For example, where the analyte is glucose, the medication dosage determination function may include a routine in which the controller module performs an algorithm to determine an insulin dose, e.g., a bolus insulin dose, based on the concentration of glucose in the sample. In another embodiment, the medication dosage determination function may be incorporated with an administering routine wherein a medication dose, e.g., an insulin dose, determined according to the dosage determination function described above is administered to the subject via a medication delivery device, e.g., a needle, syringe, external infusion device such as an ambulatory pump, an implantable pump, catheter, inhaler, transdermal patch, or one or more combinations thereof. In another embodiment, the administering routine includes administering a medication dose, e.g., an insulin dose, determined according to the medication dosage determination function to the subject via a medication delivery device positioned at a distance from the analyte meter and in communication with the analyte meter. Further, the determined medication dose, e.g., a bolus dose, may be displayed to the user via optional display unit 62 of analyte meter 10.


In certain embodiments, the controller module includes programming to perform medication dosage calculation functions, such as a single-dose calculation function for injection of, e.g., rapid acting insulin and/or long acting insulin. Analyte meters which include medication dosage calculation functions and methods of performing the dosage calculation functions are described, for example, in U.S. application Ser. Nos. 11/396,182, now U.S. Pat. No. 8,226,891, and 61/149,989, the disclosures of which are incorporated by reference herein. In one embodiment, the controller module is configured to perform a bolus calculation function. For example, the controller module may be configured to determine a bolus dosage, e.g., an insulin bolus dosage, based on the signal received from the analyte test strip. In one embodiment the controller module is configured to perform an algorithm to determine a medication dosage based on a determined concentration of analyte. The in vitro analyte meter 10 may be programmed to automatically enter into a medication dosage calculation mode to, for example, calculate and/or select a medication dosage amount based on information stored in the analyte meter 10 (such as the patient's insulin sensitivity, for example), and/or prompt the patient to provide additional information, such as the amount of carbohydrate to be ingested by the patient for determination of, for example, a carbohydrate bolus dosage determination. In another embodiment, the analyte meter 10 may be programmed to prompt the user to select whether to retrieve a predetermined or preprogrammed medication dosage amount such as, for example, a correction bolus or a carbohydrate bolus, following the display of the determined analyte concentration from an in vitro analyte test strip. In this manner, in one embodiment of the present disclosure, analyte meter 10 may be configured to automatically prompt a user to select whether a medication dosage determination is desired following analyte testing using an in vitro analyte test strip.


In certain embodiments, analyte meter 10 includes an optional medication delivery device or system (not shown), e.g., coupled therewith. Additional information regarding medication delivery devices or systems, such as, for example, integrated systems, is provided, for example, in U.S. Patent Application Publication No. US2006/0224141, published on Oct. 5, 2006, titled “Method and System for Providing Integrated Medication Infusion and Analyte Monitoring System”, and U.S. Patent Application Publication No. US2004/0254434, published on Dec. 16, 2004, titled “Glucose Measuring Module and Insulin Pump Combination,” the disclosure of each of which is incorporated by reference herein. Medication delivery devices which may be provided with analyte meter 10 include, e.g., a needle, syringe, pump, catheter, inhaler, transdermal patch, injection pen, and the like, or combinations thereof. For example, a medication delivery device or system may be in the form of a drug delivery injection pen such as a pen-type injection device incorporated within housing 20 of analyte meter 10, or as part of an in vivo integrated system such as may be incorporated into a component of system 100 (e.g., integrated with control unit 220 and/or mounting unit 24 and/or housing 120. Additional information is provided in U.S. Pat. Nos. 5,536,249 and 5,925,021, the disclosures of each of which are incorporated by reference herein.


The medication delivery system may be used for injecting a dose of medication, such as insulin, into a patient based on a prescribed medication dosage, and may be automatically updated with dosage information received from the controller module of analyte meter 10. In another embodiment, the medication dosage of the medication delivery system may include manual entry of dosage changes made through, for example, optional input 64 coupled to the housing 20 of analyte meter 10. Medication dosage information associated with the medication delivery system may be displayed on an optional display unit 62 disposed on housing 20 of analyte meter 10.


Analyte meter 10 may be a component of one or more analyte detection systems. For example, an analyte detection system according to the present disclosure may include analyte meter 10 or integrated system 100 as described herein (see, for example, FIG. 5) in addition to one or more sample acquisition and/or testing elements. In one embodiment, an analyte detection system according to the present disclosure includes an in vitro analyte test strip, e.g., an in vitro analyte test strip and a lancet.


In some embodiments, a lancet and an in vitro analyte test strip are receivable into the housing of the analyte meter 10. In other embodiments, the lancet and the test strip are not integrated into the housing of the analyte meter 10, but are instead included in the system as separate components.


Where the test strip is integrated into the housing of an analyte meter 10, the housing may be configured to hold one or more cartridges or magazines containing test strips to be used in the operation of the system. Similarly, where the lancet is integrated into the housing of an analyte meter 10, the housing may be configured to hold one or more cartridges or magazine containing lancets to be used in the operation of the system.


Additional systems incorporating the analyte meters described herein will be readily apparent to those of ordinary skill in the art upon reading the present disclosure.


In some embodiments, the analyte meter 10 includes an optional communication device (not shown), e.g., a receiver and/or transmitter for communicating with another device, e.g., a medication delivery device and/or a personal computing system (PC, notebook, laptop, etc. mobile phone, PDA, e.g., using a health management system such as the CoPilot™ system available from Abbott Diabetes Care Inc., Alameda, Calif. The communication device may be configured for wired or wireless communication, including, but not limited to, radio frequency (RF) communication, Zigbee® communication protocols, WiFi, Bluetooth® communication protocols, and cellular communication, such as code division multiple access (CDMA) or Global System for Mobile (GSM) communications.


In one embodiment, analyte meter 10 includes a wireless communication device, wherein the wireless communication device is configured for bi-directional radio frequency (RF) communication with other devices to transmit and/or receive data to and from the analyte meter 10. In one embodiment, the communication device is configured to include physical ports or interfaces such as a USB port, an RS-232 port, or any other suitable electrical connection port to allow data communication between the analyte meter 10 and other external devices such as a computer terminal (for example, at a user's home, physician's office or in hospital environment), an external medical device, such as an infusion device or including an insulin delivery device, or other devices that are configured for similar complementary data communication. In one embodiment, the communication device is configured for infrared communication, Bluetooth® communication, or any other suitable wireless communication mechanism to enable the analyte meter 10 for communication with other devices such as infusion devices, analyte monitoring devices, computer terminals and/or networks, communication enabled mobile telephones, personal digital assistants, or any other communication devices which the patient or user of the analyte meter may use in conjunction therewith, in managing the treatment of a health condition, such as diabetes.


In one embodiment, the analyte meter is configured to wirelessly communicate with a server device, e.g., using a common standard such as 802.11 or Bluetooth® RF protocol, or an IrDA infrared protocol. The server device may include another portable device, such as a Personal Digital Assistant (PDA) or notebook computer, or a larger device such as a desktop computer, appliance, etc. In some embodiments, the server device has a display, such as a liquid crystal display (LCD), as well as an input device, such as buttons, a keyboard, mouse or touch-screen. With such an arrangement, the user may control the meter indirectly by interacting with the user interface(s) of the server device, which in turn interacts with the meter across a wireless link.


In certain embodiments, the in vitro meters described herein may be combined with in vivo analyte testing systems to provide an integrated system. Embodiments include in vitro blood glucose meters having moveable in vitro analyte test strip contacting portions as part of, including coupled to, e.g., integrated with, an in vivo analyte testing system. In vivo systems include an in vivo analyte sensor that is configured to be at least partially implanted in a user—in contact with biological fluid—for a period of time, to test for analyte in the contacted biological fluid continuously or semi-continuously over the period of time. Over the period of time of in vivo testing, the in vivo periodic testing may be used in conjunction with in vitro testing. For example, analyte results obtained from in vitro testing may be used to calibrate an in vivo system and/or may be used to confirm results of an in vivo system, e.g., prior to relying on the results obtained by the in vivo analyte system. The in vitro meters described herein that include an articulating portion, may be integrated into a housing of a component of an in vivo system, e.g., integrated into a housing of an in vivo sensor control unit, an in vivo receiver unit, an in vivo mounting unit, and/or other. Integrated in vivo and in vitro analyte systems are described, e.g., in U.S. Pat. Nos. 5,262,035; 5,264,104; 5,262,305; 5,320,715; 5,593,852; 6,175,752; 6,560,471; 6,746, 582, 7,299,082 and in U.S. patent application Ser. No. 10/745,878 filed Dec. 26, 2003, now U.S. Pat. No. 7,811,231, entitled “Continuous Glucose Monitoring System and Methods of Use”, each of which is incorporated herein by reference.



FIG. 5 shows an integrated analyte system 100 in which an in vitro analyte meter having a moveable in vitro analyte test strip contacting portion is also a component of an in vivo system, and specifically in this embodiment a receiver unit of an in vivo analyte system is integrated with an in vitro meter as described herein.


The integrated system 100 of FIG. 5 includes an in vivo analyte sensor 300, an in vivo sensor control unit 220, and optional mounting unit 240 that mates with the in vivo sensor control unit 220, and a receiver unit 110 to receive signals from and/or send signals to the sensor control unit, including signals related to the detection of an analyte by in vivo sensor 300. Receiver unit 110 includes a housing 120 having a first portion or sensor contacting portion 140, and at least one other portion 160, coupled together by connector 150. First portion 140 includes an in vitro analyte test strip contacting area 142 to make contact (electrical and/or mechanical) with an in vitro analyte test strip. The in vitro analyte test strip contacting portion 140 and in vitro analyte test strip contacting area 142 function analogously to the in vitro analyte test strip contacting portion 40 and in vitro analyte test strip contacting area 42 of FIGS. 1-4.


In certain embodiments, the second portion 160 of receiver 110 includes optional reporting module 162 to report results of an analyte test to a user on a frontal or user interface side, which is opposite to an opposing side. Reporting module 162 may include audible and/or visual components and in certain embodiments may include a voice user interface. In certain embodiments, one or more user function selector(s) 164 may be included. User function selector(s) 164 may include, but are not limited to, one or more buttons, a jog wheel, capacitive sensing slider inputs, keypad, and the like, or a combination thereof. In certain embodiments, some or all of the one or more user function selector(s) 164 may control aspects related to the in vivo analyte monitoring system, the integrated in vitro analyte monitoring system, or a combination thereof. Some or all of the user function selector(s) 164 may be soft keys and may control multiple functions as described above in conjunction with FIGS. 1-3.



FIGS. 6 and 7 show side views of receiver unit 110. FIG. 6 shows in vitro analyte test strip contacting portion 140 in a first position relative to the other portion 160 such that the angle beta (β) between first portion 140 and user interface side of the second portion 160 is substantially +90 degrees and −90 degrees relative to the receiver unit 110 axis L3 defined by the dotted line shown in the figure (that is, approximately 180 degrees of rotation shown along the angle beta (β)). FIG. 7 shows in vitro analyte test strip contacting portion 140 rotated about pivot point 152 at connector 150 in a downward position to a second position. In this particular exemplary figure, in vitro analyte test strip head 140 is shown pivoted at various angles from about a −90 degree right angle to a +90 degree right angle to the housing. FIG. 8 shows a perspective view of receiver unit 110 of FIG. 7 with the in vitro analyte test strip contacting area pivoted in downward position to a second position relative to housing 160, and with an in vitro analyte test strip 80 being contacted with the in vitro analyte test strip contacting area 142. In this manner, analyte testing is facilitated by the downward pivot of the in vitro analyte test strip contacting area 142 because the user is able to contact sample with the test strip and view the results on display 162 simultaneously without having to re-orient the receiver unit 110.


Accordingly, as described herein embodiments include in vitro glucose meters for contacting an in vitro glucose test strip and providing the presence and/or concentration of glucose from a sample applied to the in vitro glucose test strip. Embodiments include meters having an in vitro glucose test strip contacting portion pivotally mounted to a user interface portion of the meter so that the in vitro test strip contacting portion is selectively pivotable relative to the user interface portion. An in vitro glucose test strip contacting portion may be pivotable towards the user interface portion and/or away from the user interface portion, e.g., towards and/or away from a reporting module of a user interface portion. A reporting module may be an audio and/or visual reporting module, e.g., a visual display.


An in vitro glucose test strip contacting portion may be pivotable to provide an angle of about 90 degrees relative to the user interface portion, e.g., towards and/or away from the user interface portion.


An in vitro test strip contacting portion may include an in vitro glucose test strip port.


An in vitro glucose test strip contacting portion may pivot through a range of about 180 degrees e.g., without the corresponding movement of a user interface portion.


A meter may include a lock to lock the in vitro glucose test strip contacting portion in a position throughout the range.


An in vitro glucose meter may be integrated with an in vivo glucose monitoring system.


Embodiments include methods of glucose monitoring. Methods may include selectively moving an in vitro glucose test strip contacting portion of an in vitro glucose meter relative to a user interface portion of the meter; contacting an in vitro glucose test strip to the in vitro glucose test strip contacting portion; applying a biological sample to the in vitro test strip; and obtaining information about glucose from the user interface portion of the meter.


Methods may include moving the in vitro glucose test strip contacting portion towards and/or away from a user interface portion, e.g., towards and/or away from a reporting module of a user interface portion. Methods may include moving an in vitro glucose test strip contacting portion to provide an angle of about 90 degrees relative to the user interface portion of a meter.


Methods may include moving an in vitro glucose test strip contacting portion through a range of about 180 degrees, e.g., without the corresponding movement of a user interface portion.


Methods may include locking the in vitro glucose test strip contacting portion in a position throughout the range.


Methods may include integrating in vitro glucose meter with an in vivo glucose monitoring system, and obtaining glucose information from in vivo glucose monitoring and from in vitro monitoring.


Methods of glucose testing may also include lancing a test area to express biological fluid from the target area; contacting an in vitro glucose test strip coupled to an in vitro glucose meter to the expressed biological fluid at the target area; and pivoting a display portion of the glucose meter without substantially moving the test strip from the target area so that the display is viewable while the contacting occurs.


Embodiments include integrated glucose monitoring systems. The integrated system may include an in vivo glucose sensor for in vivo glucose testing; an in vitro glucose test strip for ex vivo glucose testing; one or more processors for processing glucose information from the in vivo sensor and the in vitro sensor; and a housing comprising an in vitro analyte test strip contacting portion pivotal relative to a user interface portion of the meter, the housing comprising a user interface to report the processed glucose information obtained from the in vivo sensor when positioned in a user and the in vitro glucose test strip when contacted with the in vitro glucose test strip contacting portion.


While the present disclosure has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the present disclosure. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present disclosure. All such modifications are intended to be within the scope of the claims appended hereto.

Claims
  • 1. An in vitro glucose meter, comprising: a housing including a user interface portion, the housing further including an in vitro glucose test strip contacting portion pivotally mounted to the user interface portion of the housing so that the in vitro glucose test strip contacting portion is selectively pivotable relative to the user interface portion, wherein the in vitro glucose test strip contacting portion pivots through a range of about 180 degrees, and further comprising a lock to substantially fix the in vitro glucose test strip contacting portion in a position throughout the range.
  • 2. The meter of claim 1, wherein the in vitro glucose test strip contacting portion is pivotable towards a reporting module of the user interface portion.
  • 3. The meter of claim 2, wherein the reporting module comprises a display.
  • 4. The meter of claim 1, wherein the in vitro glucose test strip contacting portion is pivotable away from a reporting module of the user interface portion.
  • 5. The meter of claim 4, wherein the reporting module comprises a display.
  • 6. The meter of claim 1, wherein the in vitro glucose test strip contacting portion is pivotable to provide an angle of about 90 degrees relative to the user interface portion.
  • 7. The meter of claim 1, wherein the in vitro glucose test strip contacting portion comprises an in vitro glucose test strip port that is pivotally mounted to the user interface portion of the housing.
  • 8. The meter of claim 1, further including an in vivo glucose monitoring system integrated in the housing.
  • 9. A method, comprising: selectively moving an in vitro glucose test strip contacting portion of an in vitro glucose meter relative to a user interface portion of the meter;contacting an in vitro glucose test strip to the in vitro glucose test strip contacting portion;applying a biological sample to the in vitro glucose test strip; andobtaining information about glucose from the user interface portion of the meter; wherein the in vitro glucose meter includes a housing, the housing further including the in vitro glucose test strip contacting portion pivotally mounted to the user interface portion so that the in vitro glucose test strip contacting portion is selectively pivotable relative to the user interface portion, wherein the in vitro glucose test strip contacting portion pivots through a range of about 180 degrees, and further including a lock to substantially fix the in vitro glucose test strip contacting portion in a position throughout the range.
  • 10. The method of claim 9, comprising moving the in vitro glucose test strip contacting portion towards a reporting module of the user interface portion.
  • 11. The method of claim 9, comprising moving the in vitro glucose test strip contacting portion away from a reporting module of the user interface portion.
  • 12. The method of claim 9, comprising moving the in vitro glucose test strip contacting portion to provide an angle of about 90 degrees relative to the user interface portion.
  • 13. The method of claim 12, wherein the in vitro glucose test strip contacting portion is moveable towards the user interface portion.
  • 14. The method of claim 12, wherein the in vitro glucose test strip contacting portion is moveable away from the user interface portion.
  • 15. The method of claim 9, comprising locking the in vitro glucose test strip contacting portion in a position throughout the range.
  • 16. The method of claim 9, further comprises obtaining glucose information from in vivo glucose monitoring and from in vitro monitoring.
  • 17. An integrated glucose monitoring system, comprising: an in vivo glucose sensor for in vivo glucose testing;an in vitro glucose test strip for ex vivo glucose testing;one or more processors for processing glucose information from the in vivo glucose sensor and the in vitro glucose test strip; anda housing including a user interface portion, the housing further including an in vitro glucose test strip contacting portion pivotally mounted to the user interface portion of the housing so that the in vitro glucose test strip contacting portion is selectively pivotable relative to the user interface portion, wherein the in vitro glucose test strip contacting portion pivots through a range of about 180 degrees, and further including a lock to substantially fix the in vitro glucose test strip contacting portion in a position throughout the range.
  • 18. A method, comprising: lancing a test area to express biological fluid from a target area;contacting an in vitro glucose test strip coupled to an in vitro glucose meter to the expressed biological fluid at the target area; andpivoting a display portion of the in vitro glucose meter without substantially moving the in vitro glucose test strip from the target area so that the display portion is viewable while the in vitro glucose test strip is contacting the expressed biological fluid; wherein the in vitro glucose meter includes a housing, the housing further including an in vitro glucose test strip contacting portion pivotally mounted to the display portion so that the in vitro glucose test strip contacting portion is selectively pivotable relative to the display portion, wherein the in vitro glucose test strip contacting portion pivots through a range of about 180 degrees, and further including a lock to substantially fix the in vitro glucose test strip contacting portion in a position throughout the range.
US Referenced Citations (608)
Number Name Date Kind
3123790 Tyler Mar 1964 A
3581062 Aston May 1971 A
3926760 Allen et al. Dec 1975 A
3949388 Fuller Apr 1976 A
4036749 Anderson Jul 1977 A
4040547 Dickey Aug 1977 A
4055175 Clemens et al. Oct 1977 A
4129128 McFarlane Dec 1978 A
4245634 Albisser et al. Jan 1981 A
4327725 Cortese et al. May 1982 A
4344438 Schultz Aug 1982 A
4349728 Phillips et al. Sep 1982 A
4373527 Fischell Feb 1983 A
4411267 Heyman Oct 1983 A
4419794 Horton et al. Dec 1983 A
4425920 Bourland et al. Jan 1984 A
4478976 Goertz et al. Oct 1984 A
4494950 Fischell Jan 1985 A
4509531 Ward Apr 1985 A
4514276 Covington et al. Apr 1985 A
4527240 Kvitash Jul 1985 A
4538616 Rogoff Sep 1985 A
4619793 Lee Oct 1986 A
4671288 Gough Jun 1987 A
4685466 Rau Aug 1987 A
4703756 Gough et al. Nov 1987 A
4711247 Fishman Dec 1987 A
4729672 Takagi Mar 1988 A
4731726 Allen, III Mar 1988 A
4749985 Corsberg Jun 1988 A
4757022 Shults et al. Jul 1988 A
4777953 Ash et al. Oct 1988 A
4779618 Mund et al. Oct 1988 A
4854322 Ash et al. Aug 1989 A
4890620 Gough Jan 1990 A
4895147 Bodicky et al. Jan 1990 A
4925268 Iyer et al. May 1990 A
D310167 Reber Aug 1990 S
4953552 DeMarzo Sep 1990 A
4986271 Wilkins Jan 1991 A
4988341 Columbus et al. Jan 1991 A
4995402 Smith et al. Feb 1991 A
5000180 Kuypers et al. Mar 1991 A
5002054 Ash et al. Mar 1991 A
5013161 Zaragoza et al. May 1991 A
5019974 Beckers May 1991 A
5050612 Matsumura Sep 1991 A
5054170 Otrusina Oct 1991 A
5055171 Peck Oct 1991 A
5082550 Rishpon et al. Jan 1992 A
5106365 Hernandez Apr 1992 A
5122925 Inpyn Jun 1992 A
5140985 Schroeder et al. Aug 1992 A
5165407 Wilson et al. Nov 1992 A
5201858 Otrusina Apr 1993 A
5238729 Debe Aug 1993 A
5246867 Lakowicz et al. Sep 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264105 Gregg et al. Nov 1993 A
5279294 Anderson et al. Jan 1994 A
5285792 Sjoquist et al. Feb 1994 A
5293877 O'Hara et al. Mar 1994 A
5299571 Mastrototaro Apr 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
D348355 Scheid et al. Jul 1994 S
5340722 Wolfbeis et al. Aug 1994 A
5342789 Chick et al. Aug 1994 A
5356786 Heller et al. Oct 1994 A
5360404 Novacek et al. Nov 1994 A
5370622 Livingston et al. Dec 1994 A
5372427 Padovani et al. Dec 1994 A
5379238 Stark Jan 1995 A
5385282 Chen Jan 1995 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5408999 Singh et al. Apr 1995 A
5411647 Johnson et al. May 1995 A
5431160 Wilkins Jul 1995 A
5431921 Thombre Jul 1995 A
5452497 Peng Sep 1995 A
5462645 Albery et al. Oct 1995 A
5472317 Field et al. Dec 1995 A
D366957 Scheid et al. Feb 1996 S
5489414 Schreiber et al. Feb 1996 A
5497772 Schulman et al. Mar 1996 A
5507288 Bocker et al. Apr 1996 A
5509410 Hill et al. Apr 1996 A
5514718 Lewis et al. May 1996 A
5531878 Vadgama et al. Jul 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569186 Lord et al. Oct 1996 A
5582184 Erickson et al. Dec 1996 A
5584813 Livingston et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5593852 Heller et al. Jan 1997 A
5601435 Quy Feb 1997 A
5609575 Larson et al. Mar 1997 A
5613236 Tajima et al. Mar 1997 A
5620120 Tien Apr 1997 A
5628310 Rao et al. May 1997 A
5632557 Simons May 1997 A
5653239 Pompei et al. Aug 1997 A
5665222 Heller et al. Sep 1997 A
5709012 Ebashi Jan 1998 A
5711001 Bussan et al. Jan 1998 A
5711861 Ward et al. Jan 1998 A
5733044 Rose et al. Mar 1998 A
5735285 Albert et al. Apr 1998 A
5749656 Boehm et al. May 1998 A
5766131 Kondo et al. Jun 1998 A
5772586 Heinonen et al. Jun 1998 A
5791344 Schulman et al. Aug 1998 A
5806146 Chen Sep 1998 A
5807375 Gross et al. Sep 1998 A
5850954 Dong-Joo Dec 1998 A
5851197 Marano et al. Dec 1998 A
D408878 Patten Apr 1999 S
D409374 Laba et al. May 1999 S
5899855 Brown May 1999 A
5906031 Jensen May 1999 A
5925021 Castellano et al. Jul 1999 A
5942979 Luppino Aug 1999 A
5948006 Mann Sep 1999 A
5957854 Besson et al. Sep 1999 A
5961451 Reber et al. Oct 1999 A
5964993 Blubaugh, Jr. et al. Oct 1999 A
5965380 Heller et al. Oct 1999 A
5971922 Arita et al. Oct 1999 A
5988577 Phillips et al. Nov 1999 A
5995860 Sun et al. Nov 1999 A
D418119 Rowell Dec 1999 S
6001067 Shults et al. Dec 1999 A
6022368 Gavronsky et al. Feb 2000 A
6024699 Surwit et al. Feb 2000 A
6026321 Miyata et al. Feb 2000 A
6027459 Shain et al. Feb 2000 A
6049727 Crothall Apr 2000 A
6059156 Lehtinen May 2000 A
6068399 Tseng May 2000 A
6083710 Heller et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6091976 Pfeiffer et al. Jul 2000 A
6093172 Funderburk et al. Jul 2000 A
6103033 Say et al. Aug 2000 A
6105923 Robertson et al. Aug 2000 A
6117290 Say et al. Sep 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6121611 Lindsay et al. Sep 2000 A
6122351 Schlueter, Jr. et al. Sep 2000 A
6134461 Say et al. Oct 2000 A
6159147 Lichter et al. Dec 2000 A
6162611 Heller et al. Dec 2000 A
6175752 Say et al. Jan 2001 B1
6176401 Lim Jan 2001 B1
6200265 Walsh et al. Mar 2001 B1
6212416 Ward et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6254536 DeVito Jul 2001 B1
6275717 Gross et al. Aug 2001 B1
6283348 Wang Sep 2001 B1
6283761 Joao Sep 2001 B1
6283982 Levaughn et al. Sep 2001 B1
6284478 Heller et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6293962 Bishay Sep 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6306104 Cunningham et al. Oct 2001 B1
6309884 Cooper et al. Oct 2001 B1
6329161 Heller et al. Dec 2001 B1
6348640 Navot et al. Feb 2002 B1
6359444 Grimes Mar 2002 B1
6360888 McIvor et al. Mar 2002 B1
6366794 Moussy et al. Apr 2002 B1
6368141 Van Antwerp et al. Apr 2002 B1
6377828 Chaiken et al. Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
D457308 Infanti May 2002 S
6424847 Mastrototaro et al. Jul 2002 B1
6427088 Bowman, IV et al. Jul 2002 B1
6437679 Roques Aug 2002 B1
6440068 Brown et al. Aug 2002 B1
6443340 Chung et al. Sep 2002 B1
6470535 Mayne et al. Oct 2002 B1
6478736 Mault Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6514718 Heller et al. Feb 2003 B2
6520326 McIvor et al. Feb 2003 B2
6522927 Bishay et al. Feb 2003 B1
6551494 Heller et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558321 Burd et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6561978 Conn et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6564105 Starkweather et al. May 2003 B2
6565509 Say et al. May 2003 B1
6571128 Lebel et al. May 2003 B2
6572566 Effenhauser Jun 2003 B2
6576101 Heller et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6579690 Bonnecaze et al. Jun 2003 B1
6585644 Lebel et al. Jul 2003 B2
6589229 Connelly et al. Jul 2003 B1
6591125 Buse et al. Jul 2003 B1
6595919 Berner et al. Jul 2003 B2
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607509 Bobroff et al. Aug 2003 B2
6610012 Mault Aug 2003 B2
6633772 Ford et al. Oct 2003 B2
6635014 Starkweather et al. Oct 2003 B2
6648821 Lebel et al. Nov 2003 B2
6654625 Say et al. Nov 2003 B1
6659948 Lebel et al. Dec 2003 B2
6668196 Villegas et al. Dec 2003 B1
6676290 Lu Jan 2004 B1
6687546 Lebel et al. Feb 2004 B2
6689056 Kilcoyne et al. Feb 2004 B1
6694191 Starkweather et al. Feb 2004 B2
6695860 Ward et al. Feb 2004 B1
6702857 Brauker et al. Mar 2004 B2
6733446 Lebel et al. May 2004 B2
6740075 Lebel et al. May 2004 B2
6741877 Shults et al. May 2004 B1
6746582 Heller et al. Jun 2004 B2
6752299 Shetler et al. Jun 2004 B2
6758810 Lebel et al. Jul 2004 B2
6770030 Schaupp et al. Aug 2004 B1
6790178 Mault et al. Sep 2004 B1
6809653 Mann et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6811533 Lebel et al. Nov 2004 B2
6811534 Bowman, IV et al. Nov 2004 B2
6813519 Lebel et al. Nov 2004 B2
6849052 Ughigaki et al. Feb 2005 B2
6854882 Chen Feb 2005 B2
6862465 Shults et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6881551 Heller et al. Apr 2005 B2
6892085 McIvor et al. May 2005 B2
6895265 Silver May 2005 B2
6931327 Goode, Jr. et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6936006 Sabra Aug 2005 B2
6942518 Liamos et al. Sep 2005 B2
6950708 Bowman, IV et al. Sep 2005 B2
6958705 Lebel et al. Oct 2005 B2
6959211 Rule et al. Oct 2005 B2
6968294 Gutta et al. Nov 2005 B2
6971274 Olin Dec 2005 B2
6974437 Lebel et al. Dec 2005 B2
6990366 Say et al. Jan 2006 B2
6997907 Safabash et al. Feb 2006 B2
6998247 Monfre et al. Feb 2006 B2
7003336 Holker et al. Feb 2006 B2
7003340 Say et al. Feb 2006 B2
7003341 Say et al. Feb 2006 B2
7024245 Lebel et al. Apr 2006 B2
7025743 Mann et al. Apr 2006 B2
7041068 Freeman et al. May 2006 B2
7041468 Drucker et al. May 2006 B2
7052483 Wojcik May 2006 B2
7056302 Douglas Jun 2006 B2
7074307 Simpson et al. Jul 2006 B2
7081195 Simpson et al. Jul 2006 B2
7098803 Mann et al. Aug 2006 B2
7108778 Simpson et al. Sep 2006 B2
7110803 Shults et al. Sep 2006 B2
7113821 Sun et al. Sep 2006 B1
7129836 Lawson et al. Oct 2006 B2
7134999 Brauker et al. Nov 2006 B2
7136689 Shults et al. Nov 2006 B2
7171274 Starkweather et al. Jan 2007 B2
7190988 Say et al. Mar 2007 B2
7192450 Brauker et al. Mar 2007 B2
7198606 Boecker et al. Apr 2007 B2
7226978 Tapsak et al. Jun 2007 B2
7276029 Goode, Jr. et al. Oct 2007 B2
7278983 Ireland et al. Oct 2007 B2
7297151 Boecker et al. Nov 2007 B2
7299081 Mace et al. Nov 2007 B2
7299082 Feldman et al. Nov 2007 B2
7303726 McAllister et al. Dec 2007 B2
7310544 Brister et al. Dec 2007 B2
7335294 Heller et al. Feb 2008 B2
7340309 Miazga et al. Mar 2008 B2
7364592 Carr-Brendel et al. Apr 2008 B2
7366556 Brister et al. Apr 2008 B2
7379765 Petisce et al. May 2008 B2
7416541 Yuzhakov et al. Aug 2008 B2
7424318 Brister et al. Sep 2008 B2
7460898 Brister et al. Dec 2008 B2
7467003 Brister et al. Dec 2008 B2
7471972 Rhodes et al. Dec 2008 B2
7494465 Brister et al. Feb 2009 B2
7497827 Brister et al. Mar 2009 B2
7519408 Rasdal et al. Apr 2009 B2
7583990 Goode, Jr. et al. Sep 2009 B2
7591801 Brauker et al. Sep 2009 B2
7599726 Goode, Jr. et al. Oct 2009 B2
7613491 Boock et al. Nov 2009 B2
7615007 Shults et al. Nov 2009 B2
7632228 Brauker et al. Dec 2009 B2
7637868 Saint et al. Dec 2009 B2
7640048 Dobbles et al. Dec 2009 B2
7651596 Petisce et al. Jan 2010 B2
7654956 Brister et al. Feb 2010 B2
7657297 Simpson et al. Feb 2010 B2
7666149 Simons et al. Feb 2010 B2
7711402 Shults et al. May 2010 B2
7713574 Brister et al. May 2010 B2
7715893 Kamath et al. May 2010 B2
7722536 Goodnow May 2010 B2
20020013538 Teller Jan 2002 A1
20020019022 Dunn et al. Feb 2002 A1
20020022855 Bobroff et al. Feb 2002 A1
20020023852 McIvor et al. Feb 2002 A1
20020042090 Heller et al. Apr 2002 A1
20020082487 Kollias et al. Jun 2002 A1
20020103499 Perez et al. Aug 2002 A1
20020106709 Potts et al. Aug 2002 A1
20020119711 VanAntwerp et al. Aug 2002 A1
20020128594 Das et al. Sep 2002 A1
20020161288 Shin et al. Oct 2002 A1
20020165462 Westbrook et al. Nov 2002 A1
20020198444 Ughigaki et al. Dec 2002 A1
20030023317 Brauker et al. Jan 2003 A1
20030023461 Quintanilla et al. Jan 2003 A1
20030032867 Crothall et al. Feb 2003 A1
20030032874 Rhodes et al. Feb 2003 A1
20030042137 Mao et al. Mar 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030069510 Semler Apr 2003 A1
20030078481 McIvor et al. Apr 2003 A1
20030097092 Flaherty May 2003 A1
20030100040 Bonnecaze et al. May 2003 A1
20030106940 Bukowski Jun 2003 A1
20030109775 O'Neil et al. Jun 2003 A1
20030134347 Heller et al. Jul 2003 A1
20030144581 Conn et al. Jul 2003 A1
20030144608 Kojima et al. Jul 2003 A1
20030168338 Gao et al. Sep 2003 A1
20030176933 Lebel et al. Sep 2003 A1
20030187338 Say et al. Oct 2003 A1
20030199790 Boecker et al. Oct 2003 A1
20030199910 Boecker et al. Oct 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030217966 Tapsak et al. Nov 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040011671 Shults et al. Jan 2004 A1
20040040840 Mao et al. Mar 2004 A1
20040045879 Shults et al. Mar 2004 A1
20040054263 Moerman et al. Mar 2004 A1
20040064068 DeNuzzio et al. Apr 2004 A1
20040106858 Say et al. Jun 2004 A1
20040106859 Say et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040133164 Funderburk et al. Jul 2004 A1
20040135684 Steinthal et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040152622 Keith et al. Aug 2004 A1
20040155079 Shetler et al. Aug 2004 A1
20040167801 Say et al. Aug 2004 A1
20040171921 Say et al. Sep 2004 A1
20040176672 Silver et al. Sep 2004 A1
20040186362 Brauker et al. Sep 2004 A1
20040186365 Jin et al. Sep 2004 A1
20040193090 Lebel et al. Sep 2004 A1
20040199059 Brauker et al. Oct 2004 A1
20040204687 Mogensen et al. Oct 2004 A1
20040225338 Lebel et al. Nov 2004 A1
20040236200 Say et al. Nov 2004 A1
20040236251 Roe et al. Nov 2004 A1
20040254433 Bandis et al. Dec 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20040267300 Mace Dec 2004 A1
20050003470 Nelson et al. Jan 2005 A1
20050004494 Perez et al. Jan 2005 A1
20050010269 Lebel et al. Jan 2005 A1
20050027177 Shin et al. Feb 2005 A1
20050031689 Shults et al. Feb 2005 A1
20050043598 Goode, Jr. et al. Feb 2005 A1
20050070819 Poux et al. Mar 2005 A1
20050090607 Tapsak et al. Apr 2005 A1
20050101875 Semler et al. May 2005 A1
20050112169 Brauker et al. May 2005 A1
20050114068 Chey et al. May 2005 A1
20050121322 Say et al. Jun 2005 A1
20050131346 Douglas Jun 2005 A1
20050137573 McLaughlin Jun 2005 A1
20050143635 Kamath et al. Jun 2005 A1
20050154410 Conway et al. Jul 2005 A1
20050176136 Burd et al. Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050187720 Goode, Jr. et al. Aug 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050195930 Spital et al. Sep 2005 A1
20050197554 Polcha Sep 2005 A1
20050199494 Say et al. Sep 2005 A1
20050203360 Brauker et al. Sep 2005 A1
20050222518 Dib Oct 2005 A1
20050239154 Feldman et al. Oct 2005 A1
20050239156 Drucker et al. Oct 2005 A1
20050241957 Mao et al. Nov 2005 A1
20050245795 Goode, Jr. et al. Nov 2005 A1
20050245799 Brauker et al. Nov 2005 A1
20050277164 Drucker et al. Dec 2005 A1
20050287620 Heller et al. Dec 2005 A1
20060001538 Kraft et al. Jan 2006 A1
20060004303 Weidenhaupt et al. Jan 2006 A1
20060010098 Goodnow et al. Jan 2006 A1
20060015020 Neale et al. Jan 2006 A1
20060015024 Brister et al. Jan 2006 A1
20060016700 Brister et al. Jan 2006 A1
20060019327 Brister et al. Jan 2006 A1
20060020186 Brister et al. Jan 2006 A1
20060020187 Brister et al. Jan 2006 A1
20060020188 Kamath et al. Jan 2006 A1
20060020189 Brister et al. Jan 2006 A1
20060020190 Kamath et al. Jan 2006 A1
20060020191 Brister et al. Jan 2006 A1
20060020192 Brister et al. Jan 2006 A1
20060036139 Brister et al. Feb 2006 A1
20060036140 Brister et al. Feb 2006 A1
20060036141 Kamath et al. Feb 2006 A1
20060036142 Brister et al. Feb 2006 A1
20060036143 Brister et al. Feb 2006 A1
20060036144 Brister et al. Feb 2006 A1
20060036145 Brister et al. Feb 2006 A1
20060094986 Neel et al. May 2006 A1
20060166629 Reggiardo Jul 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060189863 Heller et al. Aug 2006 A1
20060195029 Shults et al. Aug 2006 A1
20060200970 Brister et al. Sep 2006 A1
20060222566 Brauker et al. Oct 2006 A1
20060226985 Goodnow et al. Oct 2006 A1
20060247508 Fennell Nov 2006 A1
20060258929 Goode, Jr. et al. Nov 2006 A1
20070016381 Kamath et al. Jan 2007 A1
20070027381 Stafford Feb 2007 A1
20070060814 Stafford Mar 2007 A1
20070073129 Shah et al. Mar 2007 A1
20070078320 Stafford Apr 2007 A1
20070078321 Mazza et al. Apr 2007 A1
20070078322 Stafford Apr 2007 A1
20070106135 Sloan et al. May 2007 A1
20070149875 Ouyang et al. Jun 2007 A1
20070163880 Woo et al. Jul 2007 A1
20070173706 Neinast et al. Jul 2007 A1
20070179404 Escutia et al. Aug 2007 A1
20070191701 Feldman et al. Aug 2007 A1
20070203407 Hoss et al. Aug 2007 A1
20070203966 Brauker et al. Aug 2007 A1
20070235331 Simpson et al. Oct 2007 A1
20070244398 Lo et al. Oct 2007 A1
20070249922 Peyser et al. Oct 2007 A1
20080009692 Stafford Jan 2008 A1
20080017522 Heller et al. Jan 2008 A1
20080021666 Goode, Jr. et al. Jan 2008 A1
20080029391 Mao et al. Feb 2008 A1
20080033254 Kamath et al. Feb 2008 A1
20080033268 Stafford Feb 2008 A1
20080039702 Hayter et al. Feb 2008 A1
20080045824 Tapsak et al. Feb 2008 A1
20080060955 Goodnow Mar 2008 A1
20080071156 Brister et al. Mar 2008 A1
20080083617 Simpson et al. Apr 2008 A1
20080086042 Brister et al. Apr 2008 A1
20080086044 Brister et al. Apr 2008 A1
20080086273 Shults et al. Apr 2008 A1
20080097246 Stafford Apr 2008 A1
20080099332 Scott et al. May 2008 A1
20080108942 Brister et al. May 2008 A1
20080114280 Stafford May 2008 A1
20080119707 Stafford May 2008 A1
20080183061 Goode, Jr. et al. Jul 2008 A1
20080183399 Goode, Jr. et al. Jul 2008 A1
20080188731 Brister et al. Aug 2008 A1
20080189051 Goode, Jr. et al. Aug 2008 A1
20080194935 Brister et al. Aug 2008 A1
20080194936 Goode, Jr. et al. Aug 2008 A1
20080194937 Goode, Jr. et al. Aug 2008 A1
20080194938 Brister et al. Aug 2008 A1
20080195232 Carr-Brendel et al. Aug 2008 A1
20080195967 Goode, Jr. et al. Aug 2008 A1
20080197024 Simpson et al. Aug 2008 A1
20080200788 Brister et al. Aug 2008 A1
20080200789 Brister et al. Aug 2008 A1
20080200791 Simpson et al. Aug 2008 A1
20080200897 Hoss et al. Aug 2008 A1
20080208025 Shults et al. Aug 2008 A1
20080214915 Brister et al. Sep 2008 A1
20080214918 Brister et al. Sep 2008 A1
20080228051 Shults et al. Sep 2008 A1
20080228054 Shults et al. Sep 2008 A1
20080242961 Brister et al. Oct 2008 A1
20080262469 Brister et al. Oct 2008 A1
20080275313 Brister et al. Nov 2008 A1
20080287764 Rasdal et al. Nov 2008 A1
20080287765 Rasdal et al. Nov 2008 A1
20080287766 Rasdal et al. Nov 2008 A1
20080296155 Shults et al. Dec 2008 A1
20080300476 Stafford Dec 2008 A1
20080306368 Goode, Jr. et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306435 Kamath et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20090012379 Goode, Jr. et al. Jan 2009 A1
20090018424 Kamath et al. Jan 2009 A1
20090030294 Petisce et al. Jan 2009 A1
20090036758 Brauker et al. Feb 2009 A1
20090036763 Brauker et al. Feb 2009 A1
20090043181 Brauker et al. Feb 2009 A1
20090043182 Brauker et al. Feb 2009 A1
20090043525 Brauker et al. Feb 2009 A1
20090043541 Brauker et al. Feb 2009 A1
20090043542 Brauker et al. Feb 2009 A1
20090045055 Rhodes et al. Feb 2009 A1
20090048501 Goodnow et al. Feb 2009 A1
20090062633 Brauker et al. Mar 2009 A1
20090062635 Brauker et al. Mar 2009 A1
20090076356 Simpson et al. Mar 2009 A1
20090076359 Peyser Mar 2009 A1
20090076360 Brister et al. Mar 2009 A1
20090076361 Kamath et al. Mar 2009 A1
20090082693 Stafford Mar 2009 A1
20090099436 Brister et al. Apr 2009 A1
20090102678 Stafford et al. Apr 2009 A1
20090105569 Stafford Apr 2009 A1
20090124877 Goode et al. May 2009 A1
20090124878 Goode et al. May 2009 A1
20090124879 Brister et al. May 2009 A1
20090124964 Leach et al. May 2009 A1
20090131768 Simpson et al. May 2009 A1
20090131769 Leach et al. May 2009 A1
20090131776 Simpson et al. May 2009 A1
20090131777 Simpson et al. May 2009 A1
20090137886 Shariati et al. May 2009 A1
20090137887 Shariati et al. May 2009 A1
20090143659 Li et al. Jun 2009 A1
20090143660 Brister et al. Jun 2009 A1
20090156919 Brister et al. Jun 2009 A1
20090156924 Shariati et al. Jun 2009 A1
20090163790 Brister et al. Jun 2009 A1
20090163791 Brister et al. Jun 2009 A1
20090171182 Stafford Jul 2009 A1
20090178459 Li et al. Jul 2009 A1
20090182217 Li et al. Jul 2009 A1
20090192366 Mensinger et al. Jul 2009 A1
20090192380 Shariati et al. Jul 2009 A1
20090192722 Shariati et al. Jul 2009 A1
20090192724 Brauker et al. Jul 2009 A1
20090192745 Kamath et al. Jul 2009 A1
20090192751 Kamath et al. Jul 2009 A1
20090203981 Brauker et al. Aug 2009 A1
20090204341 Brauker et al. Aug 2009 A1
20090216103 Brister et al. Aug 2009 A1
20090240120 Mensinger et al. Sep 2009 A1
20090240128 Mensinger et al. Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090242399 Kamath et al. Oct 2009 A1
20090242425 Kamath et al. Oct 2009 A1
20090247855 Boock et al. Oct 2009 A1
20090247856 Boock et al. Oct 2009 A1
20090287073 Boock et al. Nov 2009 A1
20090287074 Shults et al. Nov 2009 A1
20090299155 Yang et al. Dec 2009 A1
20090299156 Simpson et al. Dec 2009 A1
20090299162 Brauker et al. Dec 2009 A1
20090299276 Brauker et al. Dec 2009 A1
20100010324 Brauker et al. Jan 2010 A1
20100010331 Brauker et al. Jan 2010 A1
20100010332 Brauker et al. Jan 2010 A1
20100016687 Brauker et al. Jan 2010 A1
20100016698 Rasdal et al. Jan 2010 A1
20100022855 Brauker et al. Jan 2010 A1
20100030038 Brauker et al. Feb 2010 A1
20100030053 Goode, Jr. et al. Feb 2010 A1
20100030484 Brauker et al. Feb 2010 A1
20100030485 Brauker et al. Feb 2010 A1
20100036215 Goode, Jr. et al. Feb 2010 A1
20100036216 Goode, Jr. et al. Feb 2010 A1
20100036222 Goode, Jr. et al. Feb 2010 A1
20100036223 Goode, Jr. et al. Feb 2010 A1
20100036225 Goode, Jr. et al. Feb 2010 A1
20100041971 Goode, Jr. et al. Feb 2010 A1
20100045465 Brauker et al. Feb 2010 A1
20100049024 Saint et al. Feb 2010 A1
20100052293 Brooks et al. Mar 2010 A1
20100063373 Kamath et al. Mar 2010 A1
20100076283 Simpson et al. Mar 2010 A1
20100076290 Bernstein et al. Mar 2010 A1
20100081908 Dobbles et al. Apr 2010 A1
20100081910 Brister et al. Apr 2010 A1
20100087724 Brauker et al. Apr 2010 A1
20100096259 Zhang et al. Apr 2010 A1
20100099970 Shults et al. Apr 2010 A1
20100099971 Shults et al. Apr 2010 A1
20100119693 Tapsak et al. May 2010 A1
20100121169 Petisce et al. May 2010 A1
Foreign Referenced Citations (41)
Number Date Country
4401400 Jul 1995 DE
0098592 Jan 1984 EP
0127958 Dec 1984 EP
0320109 Jun 1989 EP
0353328 Feb 1990 EP
0390390 Oct 1990 EP
0396788 Nov 1990 EP
0286118 Jan 1995 EP
1048264 Nov 2000 EP
1177802 Feb 2002 EP
2060284 May 2009 EP
WO-9625089 Aug 1996 WO
WO-9635370 Nov 1996 WO
WO-9835053 Aug 1998 WO
WO-9956613 Nov 1999 WO
WO-0049940 Aug 2000 WO
WO-0059370 Oct 2000 WO
WO-0078992 Dec 2000 WO
WO-0152935 Jul 2001 WO
WO-0154753 Aug 2001 WO
WO-0216905 Feb 2002 WO
WO-02058537 Aug 2002 WO
WO-03076893 Sep 2003 WO
WO-03082091 Oct 2003 WO
WO-2004061420 Jul 2004 WO
WO-2005089103 Sep 2005 WO
WO-2007016399 Feb 2007 WO
WO-2007027788 Mar 2007 WO
WO-2007041069 Apr 2007 WO
WO-2007041070 Apr 2007 WO
WO-2007041248 Apr 2007 WO
WO-2007120363 Oct 2007 WO
WO-2007143225 Dec 2007 WO
WO-2008031106 Mar 2008 WO
WO-2008031110 Mar 2008 WO
WO-2008039944 Apr 2008 WO
WO-2008051920 May 2008 WO
WO-2008051924 May 2008 WO
WO-2008103620 Aug 2008 WO
WO-2008150917 Dec 2008 WO
WO-2009062675 May 2009 WO
Non-Patent Literature Citations (44)
Entry
American Heritage Dictionary, 4th ed., Houghton Mifflin Company, 2000, pp. 782.
Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519-1526.
Aussedat, B., et al., “A User-Friendly Method for Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycaemic Alarm”, Biosensors & Bioelectronics, vol. 12, No. 11, 1997, pp. 1061-1071.
Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 25-33.
Blank, T. B., et al., “Clinical Results From a Non-Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10.
Brooks, S. L., et al., “Development of an On-Line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987/88, pp. 45-56.
Cass, A. E., et al., “Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose”, Analytical Chemistry, vol. 56, No. 4, 1984, 667-671.
Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on ‘Wired’ Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240-1244.
Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, 2003, pp. 769-779.
Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004.
Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, pp. 198.
Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?”, 2002, pp. 250.
Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303-1304.
Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549.
Lortz, J., et al., “What is Bluetooth? We Explain the Newest Short-Range Connectivity Technology”, Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74.
Malin, S. F., et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectoscopy”, Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658.
McGarraugh, G., et al., “Glucose Measurements Using Blood Extracted from the Forearm and the Finger”, TheraSense, Inc., 2001, 16 Pages.
McGarraugh, G., et al., “Physiological Influences on Off-Finger Glucose Testing”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376.
McKean, B. D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532.
Pickup, J., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy”, Biosensors, vol. 3, 1987/88, pp. 335-346.
Pickup, J., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer”, Diabetologia, vol. 32, 1989, pp. 213-217.
Pishko, M. V., et al., “Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels”, Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272.
Quinn, C. P., et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors”, The American Physiological Society, 1995, E155-E161.
Roe, J. N., et al., “Bloodless Glucose Measurements”, Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241.
Sakakida, M., et al., “Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations”, Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158.
Sakakida, M., et al., “Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane”, Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322.
Salehi, C., et al., “A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors”, Analytical Letters, vol. 29, No. 13, 1996, pp. 2289-2308.
Schmidt, F. J., et al., “Calibration of a Wearable Glucose Sensor”, The International Journal of Artificial Organs, vol. 15, No. 1, 1992, pp. 55-61.
Schmidtke, D. W., et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin”, Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294-299.
Shaw, G. W., et al., “In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406.
Shichiri, M., et al., “Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas”, Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers”, Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17-20.
Shichiri, M., et al., “Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor”, Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309-313.
Shichiri, M., et al., “Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed-Loop Prosthetic Systems, Chapter 15, 1985, pp. 197-210.
Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298-301.
Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor”, The Lancet, 1982, pp. 1129-1131.
Shults, M. C., et al., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937-942.
Sternberg, R., et al., “Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27-40.
Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255-261.
Turner, A., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85-115.
Updike, S. J., et al., “Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Body: Continuous in vivo Monitoring, Chapter 4, 1997, pp. 117-137.
Velho, G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957-964.
Wiley Electrical and Electronics Engineering Dictionary, John Wiley & Sons, Inc., 2004, pp. 141, 142, 548, 549.
Wilson, G. S., et al., “Progress Toward the Development of an Implantable Sensor for Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613-1617.
Related Publications (1)
Number Date Country
20100331653 A1 Dec 2010 US